These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31540711)

  • 21. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Wallach AI; Waltz M; Casper TC; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Graves J; Harris Y; Lotze TE; Mar S; Moodley M; Ness JM; Rensel M; Rodriguez M; Rose JW; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Charvet LE; Krupp LB
    Mult Scler; 2020 Dec; 26(14):1938-1947. PubMed ID: 31775571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cognitive Impairment in Multiple Sclerosis].
    Niino M; Miyazaki Y
    Brain Nerve; 2020 May; 72(5):509-515. PubMed ID: 32381748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up.
    Amato MP; Goretti B; Ghezzi A; Lori S; Zipoli V; Moiola L; Falautano M; De Caro MF; Viterbo R; Patti F; Vecchio R; Pozzilli C; Bianchi V; Roscio M; Martinelli V; Comi G; Portaccio E; Trojano M;
    Neurology; 2010 Sep; 75(13):1134-40. PubMed ID: 20876467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
    Portaccio E; Bellinvia A; Razzolini L; Pastò L; Goretti B; Niccolai C; Fonderico M; Zaffaroni M; Pippolo L; Moiola L; Falautano M; Celico C; Viterbo R; Patti F; Chisari C; Gallo P; Riccardi A; Borghi M; Bertolotto A; Simone M; Pozzilli C; Bianchi V; Roscio M; Martinelli V; Comi G; Filippi M; Trojano M; Ghezzi A; Amato MP;
    Neurology; 2022 Apr; 98(16):e1626-e1636. PubMed ID: 35437271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
    Meca-Lallana JE; Prieto-González JM; Jimenez-Veiga J; Carreón-Guarnizo E; Jiménez-Martín I; Hernández-Clares R; Sistiaga-Berrondo A; Carles-Dies R; García-Molina E; Cerdán-Sánchez M; Costa-Arpín E; Croitoru I; Castillo-Triviño T; Iniesta-Martinez F; García-Pérez E; Olascoaga-Urtaza J
    Mult Scler Relat Disord; 2019 Feb; 28():50-56. PubMed ID: 30553169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
    Bagert B; Camplair P; Bourdette D
    CNS Drugs; 2002; 16(7):445-55. PubMed ID: 12056920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.
    Miller E; Morel A; Redlicka J; Miller I; Saluk J
    Curr Neuropharmacol; 2018; 16(4):475-483. PubMed ID: 29119933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis.
    Bellinvia A; Portaccio E; Amato MP
    Expert Opin Pharmacother; 2023 Mar; 24(4):435-451. PubMed ID: 36542754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-road assessment of fitness-to-drive in persons with MS with cognitive impairment: A prospective study.
    Morrow SA; Classen S; Monahan M; Danter T; Taylor R; Krasniuk S; Rosehart H; He W
    Mult Scler; 2018 Oct; 24(11):1499-1506. PubMed ID: 28782411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.
    De Giglio L; Marinelli F; Barletta VT; Pagano VA; De Angelis F; Fanelli F; Petsas N; Pantano P; Tomassini V; Pozzilli C
    CNS Drugs; 2017 Feb; 31(2):161-168. PubMed ID: 27995531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life and cognitive functions in early onset multiple sclerosis.
    Lanzillo R; Chiodi A; Carotenuto A; Magri V; Napolitano A; Liuzzi R; Costabile T; Rainone N; Freda MF; Valerio P; Brescia Morra V
    Eur J Paediatr Neurol; 2016 Jan; 20(1):158-63. PubMed ID: 26387071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing easy to perform routine MRI measurements as potential surrogates for cognitive impairment in MS.
    Morrow SA; Menon S; Rosehart H; Sharma M
    Clin Neurol Neurosurg; 2017 Feb; 153():73-78. PubMed ID: 28061362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
    Fuchs TA; Wojcik C; Wilding GE; Pol J; Dwyer MG; Weinstock-Guttman B; Zivadinov R; Benedict RH
    Mult Scler; 2020 Feb; 26(2):245-252. PubMed ID: 30615562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging with multiple sclerosis: prevalence and profile of cognitive impairment.
    Branco M; Ruano L; Portaccio E; Goretti B; Niccolai C; Patti F; Chisari C; Gallo P; Grossi P; Ghezzi A; Roscio M; Mattioli F; Bellomi F; Simone M; Viterbo RG; Amato MP
    Neurol Sci; 2019 Aug; 40(8):1651-1657. PubMed ID: 31011932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive Aspects in Multiple Sclerosis.
    Lisak M; Špiljak B; Pašić H; Trkanjec Z
    Psychiatr Danub; 2021 Dec; 33(Suppl 13):177-182. PubMed ID: 35150483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Meijer KA; Eijlers AJC; Douw L; Uitdehaag BMJ; Barkhof F; Geurts JJG; Schoonheim MM
    Neurology; 2017 May; 88(22):2107-2114. PubMed ID: 28468841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.